On World Cancer Day, we are proud to renew our commitment to the people behind every cancer diagnosis – individuals with unique circumstances, treatment needs, and hopes for the future.
The current World Cancer Day theme, United by Unique, reminds us that effective cancer care begins with listening. Adalvo’s approach is about responding to real patient needs: identifying where access gaps exist and working to bring differentiated therapies to the people who need them, quickly and reliably.
Our oncology portfolio includes 34 therapies, with six new treatments added in the past year alone:
- Osimertinib for EGFR-mutated lung cancer
- Alectinib for ALK-positive lung cancer
- Abemaciclib for HR-positive breast cancer
- Acalabrutinib for blood cancers including chronic lymphocytic leukaemia
- Darolutamide for advanced prostate cancer
- Trifluridine/Tipiracil for metastatic colorectal cancer.
Every journey is unique
Each patient's journey is different, which is why we're developing value-added medicines, like our Lenvatinib oral solution. It’s designed to improve treatment adherence and offer flexible dosing for patients who struggle to swallow capsules.
Our ‘asset-light’ model means we can move with agility, focusing our resources where they matter most: getting high-quality treatments to patients faster.
World Cancer Day reminds us that behind every therapy launch, every regulatory milestone, every partnership, there are people waiting – and that sense of urgency drives everything we do.
For more information about Adalvo's oncology portfolio, please contact one of the team today.